Bydureon effects persists for years
This article was originally published in Scrip
Executive Summary
In a poster presentation at the American Diabetes Association 71st annual meeting in San Diego, Amylin and Eli Lilly showed that the effects of Bydureon, the long-acting formulation of the GLP-1 analogue, exenatide, had a robust efficacy "out to three years", and there was a significant reduction in weight (5.1 pounds) compared to baseline.